Gilead Sciences announced Wednesday that a division of the National Institutes of Health will be releasing positive early results of a clinical trial of its drug remdesivir, a potential treatment for coronavirus, sending markets sharply up at opening of trading.“Gilead Sciences is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ (NIAID) study of the investigational antiviral remdesivir for the treatment of covid-19,” the company said in an early-morning statement. “We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing.”Gilead did not provide specifics or characterize the results in the brief statement. NIAID confirmed it planned an announcement later Wednesday at a briefing by President Trump’s coronavirus task force.In brief remarks at the White House Wednesday, Anthony Fauci, chief of NIAID and a key advisor on Trump’s task force, said the result “doesn’t seem like a knockout” but that it was a strong “proof of concept” for the drug, according to a pool report.Fauci said the drug had produced only a minor improvement on deaths — 11 percent for the placebo arm of the study and 8 percent for those treated with remdesivir. He


Continue To Full Article